Stromedix Wins Patent For Lead Drug
Luke Timmerman1/23/09
Stromedix, a Cambridge, MA-based biotech company, said it has received a U.S. patent that protects its lead drug for fibrosis, STX-100. The patent, U.S. 7,465,449, covers high-affinity monoclonal antibodies and antigen-binding fragments that block a target on cells that is an important regulator of fibrosis and tissue injury. Rebecca described this technology that Stromedix acquired from Biogen Idec back in April.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
